Please ensure Javascript is enabled for purposes of website accessibility

Is Obamacare Turning Pharmacies Into Doctors?

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

And where consumers can shop for the cheapest generic drugs.

From the impact of Obamacare to cutting-edge research, biotech buyouts to Big Pharma court battles, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health care, and their implications for long-term investors. In this week's edition, the team talks about Novartis' patent dispute, stocks that have both popped and plummeted, and the companies our analysts will be watching in the coming days.

In the following segment, health-care analyst David Williamson discusses two big developments with retail pharmacies that are affecting consumers. Watch and find out why you might be ditching your family doctor for a Walgreen and where you can get the cheapest generic drugs. Fool on!

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$43.71 (1.56%) $0.67
Costco Wholesale Corporation Stock Quote
Costco Wholesale Corporation
COST
$470.76 (1.24%) $5.77
CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$98.05 (0.26%) $0.25
Novartis AG Stock Quote
Novartis AG
NVS
$91.46 (0.22%) $0.20
Rite Aid Corporation Stock Quote
Rite Aid Corporation
RAD
$5.75 (5.70%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.